Skip Navigation.

PHARMA IN BRIEF

September 8th, 2007

Title: PHARMA IN BRIEF ,  Chemical Market Reporter, 00900907, 9/10/2001, Vol. 260, Issue 10

Section: Section 2 MARKETS: PHARMACEUTICALS & FINE CHEMICALS

ADVANCED PHARMA, a privately held specialty pharmaceutical company focused on the development of novel anti-infective products, is now called Advancis Pharmaceutical Corp.

ESTRADIOL The FDA has accepted Novavax Inc.’s new drug application for Estrasorb (17-beta-estradiol) lotion, a topical transdermal estrogen replacement therapy for symptomatic menopausal women. As a result, Novavax has received a $2.5 million milestone payment from King Pharmaceuticals Inc.

CELL GENESYS Inc. has completed the acquisition of Calydon Inc., a private biotechnology company focused on developing therapeutic products for cancer.

CIALIS Icos Corp.’s new drug application for Cialis, a treatment for erectile dysfunction, has been accepted by the FDA.

PHENTERMINE HYDROCHLORIDE Able Laboratories Inc. has received FDA approval for phentermine hydrochloride tablets USP, 37.5 mg, phentermine hydrochloride capsules USP, 30 mg, and phentermine hydrochloride capsules USP, 30 mg (beads).

SECRETIN The FDA has granted Fast Track designation for Repligen Corp.’s secretin for the treatment of pediatric autism.


Copyright of Chemical Market Reporter is the property of Schnell Publishing Company Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Chemical Market Reporter, 9/10/2001, Vol. 260 Issue 10, p8, 1p

Consultants try the HARD SELL

September 8th, 2007

Title: Consultants try the HARD SELL ,  By: Rosenfeld, Jill, Fast Company, 10859241, Mar2001, Issue 44

IS CORPORATE viagra THE NEXT BIG IDEA OR JUST ANOTHER LIMP NOTION?

DO YOU WORK FOR A COMPANY THAT SUFFERS FROM performance dysfunction? Then this may be the time to get a fresh surge of energy with a breakthrough treatment from the consulting world: corporate viagra . It’s a new remedy that’s getting a hard sell from some overstimulated consultants who provide a “dose of viagra ” for businesses that have gone soft.

Take, for example, Thomas A. FitzGerald, author of an article on corporate viagra for the consulting newsletter the CEO Refresher: “FLACCID!” the article begins, as a fictional female board member loudly interrupts a presentation by the board’s chairman.

“IMPOTENT!” she bellows. What the company really needs, the screaming board member suggests, is “a strong dose of viagra !”

“Corporate Impotence, especially the early stage, is the first indicator of deeprooted problems,” FitzGerald explains.

To help limp companies, FitzGerald offers a Corporate Vitality Profile (CVP) and a dose of corporate viagra . But FitzGerald isn’t the only consultant who’s been flogging this metaphor. The Houston, Texas—based consulting firm Extreme Achievers claims to offer better results than viagra does: “Unlike with the male anti-impotence drug viagra , the Extreme Achievers Quotient Survey is the amazing pill that lets both men and women achieve amazing feats of performance—with no adverse side effects!” asserts the company Web site.

The Consultant Debunking Unit (CDU) decided to go after some hard facts and find out whether this metaphor is capable of sustaining itself.

First stop: Giles Brindley, professor emeritus of physiology at the University of London. Brindley, a true pioneer in the world of urology, is one of the best-known researchers in the area of impotence, due to a prominent demonstration he made at a urology conference in 1983.

At that convention, Brindley injected himself with a drug that he’d been testing and offered a full monty to an audience of colleagues. It was the first time that urologists had witnessed an “erection by injection.” Boston University Medical Center urologist Irwin Goldstein recalled the experience in a New York Times Magazine article last year: “He walked down the aisle and let us touch it. People couldn’t believe it wasn’t an implant.”

What about corporate viagra ? “The problem is that viagra is a temporary treatment,” Brindley points out. “ viagra doesn’t treat the problem itself—just the symptom. And I wouldn’t recommend taking viagra every day. It’s a new drug, and you just can’t know what the side effects might be.”

Does Brindley have a better suggestion? “If I were a consultant, I might consider saying that I’m like an injection of prostaglandin E-1, which men are more likely to respond to than they are to viagra ,” he says. “Prostaglandin E-1 gives you an erection no matter what, provided your blood system is intact. Of course, the drug still produces only a temporary solution.”

Next stop for the CDU: the vacuum erection system, arguably the oldest and most American of impotence remedies. In the mid-1970s, Geddings Osbon, who had founded a successful tire-retreading business, invented the vacuum pump by hooking a bicycle pump to a truck-tire valve, reversing the cylinder to create negative pressure, and applying it to his nether parts. His tire rose, and an invention was born.

Osbon has since passed away, but his son and grandson carry on the family tradition of manufacturing vacuum systems. “The pump allows you to achieve the fullest erection physically possible,” says grandson Michael Osbon. “It gives you the firmest results.”

What about viagra for companies? Does it hold up? “I’d think that if you were in business, you’d want a solution that was surer than viagra ,” young Osbon says. “A lot of men contact us after they’ve had an unsuccessful experience with viagra .”

For the final word, the CDU turned to David M. Friedman, author of A Mind of Its Own: A Cultural History of the Penis, due out in November from the Free Press. Friedman first formally contemplated the subject in 1996, when he injected himself with an anti-impotence drug and chronicled the ensuing four-hour erection for Esquire.

“For the record, those shots really do work,” Friedman says. “The pump makes you cold, purple, and kind of dead. As for viagra , it doesn’t take into account the fact that there are two people in a sexual relationship. It treats the penis as the patient. There’s a word for having sex with the penis alone: ‘masturbation.’”

Which may be what consultants know how to do best.

“I’D THINK THAT IF YOU WERE IN BUSINESS, YOU’D WANT A SOLUTION THAT WAS SURER THAN viagra .”

PHOTO (COLOR):

PHOTO (COLOR):

~~~~~~~~

By Jill Rosenfeld


Copyright of Fast Company is the property of Fast Company and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Fast Company, Mar2001 Issue 44, p62, 2p

FACILITATING SEXUAL HEALTH: INTIMACY ENHANCEMENT TECHNIQUES FOR SEXUAL DYSFUNCTION

September 8th, 2007

Title: FACILITATING SEXUAL HEALTH: INTIMACY ENHANCEMENT TECHNIQUES FOR SEXUAL DYSFUNCTION ,  By: Southern, Stephen, Journal of Mental Health Counseling, 10402861, Jan99, Vol. 21, Issue 1


Technological advances afford opportunities for reclaiming sexual functioning, even among individuals with chronic illness or devastating injury. However, medical advances cannot insure that sexual outlet will facilitate intimacy in a committed relationship. Sex therapy, based on the pioneering work of Masters and Johnson, addresses dysfunction in an essential relational context. This article provides an overview of treatment strategies for promoting sexual health.

As we move toward the 21st century, technological advances afford opportunities for nearly everyone to enjoy a satisfying sex life. For example, individuals with devastating spinal cord injuries can learn to reclaim the experience of orgasm, which can be verified by PET and MRI findings, even in the absence of genital sensation (Whipple, Gerdes, & Komisaruk, 1996). Recently, the introduction of an oral medication for erectile dysfunction ( Sildenafil citrate or Viagra) provided hope for thousands of men and their partners, yet catalyzed the recurrent debate regarding the benefits and limitations of a quick fix for sexual problems (Bancroft, 1990; Tiefer, 1986). Breakthroughs in technology and advances in medicine cannot insure that sexual outlet will facilitate intimacy in a committed relationship.


SEX IS A NATURAL FUNCTION

This statement represents the cornerstone of sex therapy pioneered at Masters & Johnson Institute. The goal of any effective treatment of sexual dysfunction involves removing the roadblocks to the natural expression of sexuality within an intimate relationship. These roadblocks may be organic or psychogenic. Yet, ultimately, sexual health should be defined in the context of facilitating intimacy in an ongoing relationship.

Intimacy is a core component of love. The word intimacy has depth in its very meaning. It was originally derived from the Latin intimus meaning “inner” or “inmost.” The French intime signifies “deep, fervent, ardent.” The Italian intimo means “close” or “innermost.” The derivation of intimacy indicates there is an internal, emotional experience by which each partner is drawn close to the other. Sexual intercourse is a powerful symbol of the loving embrace of intimacy.

When individuals experience difficulty in sexual functioning, they tend to avoid opportunities for physical and emotional closeness (McCarthy, 1997; Moret, Glaser, Page, & Bergeron, 1998). Sex therapy techniques can be used not only to remove roadblocks linked to specific sexual disorders, but also to strengthen intimacy in committed relationships. Although the “medicalization” of sexual dysfunction treatment has resulted in underemphasis of dyadic issues (Ackerman & Carey, 1995; Tiefer, 1986), classic models of sex therapy (e.g., Kaplan, 1979; Masters & Johnson, 1970) and more contemporary approaches (Barbach, 1997; Rosen & Leiblum, 1995; Schnarch, 1997; Schwartz & Masters, 1988) focus on the centrality of couple intimacy enhancement. In the case of erectile dysfunction, sex therapy outcome has been associated with improvement in dyadic communication, expression of affection, and support for partner adjustment (Hawton, Catalan & Fagg, 1992).

The purpose of this article is to provide a brief overview of intimacy enhancing treatment approaches for selected sexual dysfunctions. Some attention is devoted to recent advances in sexual medicine. However, the present overview is offered to counterbalance the medicalization of sexual health by emphasizing the importance of relational intimacy in disrupting syndromes of sexual dysfunction.


TYPES OF SEXUAL DYSFUNCTION

If intimacy is the goal of sexual health, then the relationship is the major unit of analysis in the assessment or treatment of sexual dysfunction (Hirst & Watson, 1997; McCabe, 1997; Masters & Johnson, 1970). In the 1970s, when the profession of sex therapy was growing rapidly in acceptance, roadblocks to natural sexual functioning were viewed almost exclusively as emotional or relational in nature. Ninety percent of sexual dysfunction cases were treated as psychogenic in origin (Kaplan, 1983; Wincze & Carey, 1991). Today, etiology in most cases is determined to be organic, primarily because enhanced technology permits the identification of subtle anatomical and physiological features It is likely that almost all cases of sexual dysfunction involve mixed etiology with psychogenic and organic factors (Burvat, Burvat-Herbaut, Lemaire, Marcolin, & Quittelier, 1990; Kaplan, 1983; Kellett, 1995). Although medical treatments are available, they do not necessarily address psychogenic factors or automatically contribute to intimacy. Thus, sex therapy remains an important component in the assessment and treatment of sexual dysfunction in men and women.

Assessment of sexual dysfunction involves ideally a treatment team committed to facilitating sexual health in an intimate relationship. Sexual medicine clinics (Kellett, 1995; Melman, Tiefer, & Pedersen, 1988; Renshaw, 1988; Verma, Khaitan, & Singh, 1998) include physicians and mental health professionals who possess specialized training and experience in the diagnosis and treatment of sexual problems. According to the sexual health model, there are two domains of assessment–the individual and the relationship (McCabe & Cobain, 1998). Some cases of sexual dysfunction seem to be related primarily to individual factors (e.g., vascular erectile dysfunction), while other cases are clearly relational in nature (e.g., sexual desire discrepancy). There are emotional and biological features among the many individual and relational factors in sexual dysfunction.

Comprehensive evaluation of sexual dysfunction can be tailored to the presenting problem. Particular disorders for males and females exist in each of the phases of the sexual response cycle, which consists of desire, arousal, orgasm, and resolution.

The types of dysfunction identified in the table include some conditions described in the Diagnostic and Statistical Manual of Mental Disorders (4th ed.) (American Psychiatric Association, 1994). The table includes some types or classifications recognized in clinical sexology practice (e.g., Kaplan, 1983; Wincze & Carey, 1991). The various dysfunctions may be considered either primary (lifelong) or secondary (reflecting an acquired problem often caused by another condition). In addition, some of the types are generalized, occurring across sexual situations and partners, or situational, applying only to particular settings or partners.

Each of the types of sexual dysfunction has specific diagnostic criteria. The types can be briefly described as follows. Hypoactive sexual desire refers to persistent or recurrent lack of sexual fantasy or desire for sexual activity. Sexual aversion includes persistent or recurrent avoidance of sexual outlet due to distress associated with potentially sexual stimuli. In some relationships, there is a significant difference in desire for sexual outlet, leading to frustration or discomfort for one or both partners. Sexual desire discrepancy is encountered frequently in marital and sex therapy (Beck, 1995; Kaplan, 1979; Lobitz & Lobitz, 1996; MacPhee, Johnson, & van der Veer, 1995; Schwartz & Masters, 1988; Southern, 1985).

Sexual compulsivity is a term coined by the Masters & Johnson Institute to account for hyperactive sexual fantasy and behavior, which produces adverse physical, emotional, and social consequences (Carnes, 1983, 1996; Cooper, 1998; Schwartz, 1996). The general domain of sexual compulsivity may contain paraphilias, or conditions in which sexual interest and preferred or exclusive sexual outlet is associated with a variant or unusual object, partner, or activity (e.g., cross-dressing or transvestic fetishism) (Abel & Osborn, 1992; Abel & Roleau, 1995; American Psychiatric Association, 1994; Moser, 1992). Any of the desire phase disorders can interfere with pursuit of intimate, partner-oriented sexual expression.

Erectile dysfunction includes a number of conditions in which there is difficulty attaining or maintaining sufficient erection (e.g., 70% of full erection) for penetration. The rigidity of erection varies significantly over time and may be affected by a number of situational and chronic conditions. Thus, it is useful to relate the condition to inability or difficulty in completing satisfying intercourse. There are hormonal, neurological, and vascular causes of erectile dysfunction (Burvat et al., 1990; Rowland & Slob, 1995). In addition, performance anxiety and “spectatoring,” or becoming a worried observer of sexual functioning, contribute significantly in the etiology of erectile dysfunction. This condition has been called impotence, a term with many negative and shameful connotations. Sexual arousal disorder occurs in the female when there is difficulty with lubrication or vasocongestion of the labia and clitoris. Similar to erectile dysfunction, female sexual arousal disorder may be associated with hormonal, vascular, and neurological conditions (Palace, 1995; Read, 1995). Labels such as “impotence” and “frigidity” are seldom used in professional settings; however, they are still in common usage in the general public.

Orgasm phase disorders are caused by organic and psychogenic factors. Problems with orgasm (including retrograde ejaculation in which semen is directed into the bladder rather than the urethra) may be secondary to diabetes. Inhibition of orgasm is a side effect of some medications, especially Prozac (fluoxetine hydrochloride) and other serotonin reuptake inhibitors (Ashton, Hamer, & Rosen, 1997; Seagraves, 1998). While arousal phase disorders are linked primarily to stress and anxiety, disorders of orgasm can be conceptualized as difficulty in “letting go” or facilitating the pleasurable sensations of the plateau stage of arousal. Orgasm is a reflex that will occur after an individually determined level of mental and physical stimulation. Individuals who try to maintain excessive control over the environment may have trouble experiencing orgasm (Anderson & Cyranowski, 1995; Byrne & Schulte, 1990; Heiman & LoPiccolo, 1988; Rosen & Leiblum, 1995).

Delayed ejaculation refers to difficulty in attaining orgasm, especially in the context of partner-oriented sexual activity (Apfelbaum, 1989). Some males have never experienced a climax (i.e., ejaculatory incompetence). Other males believe that they climax too quickly. The determination of rapid ejaculation (usually called “premature ejaculation”) almost always involves subjective estimates from the male and his partner about the desired duration of intercourse. Thus, relational factors play a critical role in the assessment and treatment of this dysfunction (McCarthy, 1994; Spector & Carey, 1990).

Only 40% to 50% of females are regularly orgasmic during intercourse (Masters & Johnson, 1970). The “missionary position” or “male superior” position seems to be ill-suited for stimulating the female. Many women are at least situationally anorgasmic, depending upon certain setting and partner variables. If a woman has never experienced an orgasm by any means, then she may have inhibited female orgasm. The current popular term for the condition is “preorgasmic,” suggesting that every woman has the right to realize this natural sexual function (Heiman & LoPiccolo, 1988).

Few classification systems include resolution phase disorders. Yet, if sexual compulsivity is accepted as a valid dysfunction, then it is clear that this condition extends into the resolution phase of the sexual response cycle. Ordinarily, when a male experiences ejaculation, he loses much of his erection and additional stimulation of the penis is considered neutral or aversive. Masters and Johnson (1966,1970) described the refractory period in which there is a gradually increasing period of time (or latency) between the last climax and arousability or interest in another sexual outlet. While females have the potential for multiple orgasms, in general, there is an identifiable period of time in which additional stimulation is not wanted.

The resolution period is also important in terms of bonding or attachment between loving partners (Anderson & Cyranowski, 1995; Lobitz & Lobitz, 1996). According to the sexual health model advocated in this article, in which intimacy is the primary goal, the resolution phase affords opportunity for sharing physical and emotional closeness, warm communication, and mutual respect. Whenever sex is mechanical, compulsive, or abusive, there is no intimacy. For example, the resolution of sexual intercourse may feel like one partner has used the other for masturbation. Sexual health should take into consideration the emotional components of loving partners. Intimacy dysfunction refers to a class of conditions in which sex is solitary, compulsive, or abusive to oneself or one’s partner.

Pain may occur at any point in the sexual response cycle. Obviously, pain is incompatible with pleasure and intimacy in the ongoing sexual experience. Dyspareunia occurs in both males and females. The condition is associated with pain or discomfort in the genitals, which may be a function of organic or psychogenic factors (Meana & Binik, 1994; Steege & Ling, 1993). A related conditions in females, vaginismus, involves involuntary contraction of the circumvaginal muscles such that penetration is difficult or impossible. (Read, 1995). Vaginismus is encountered among survivors of sexual abuse (Leiblum, Pervin, & Campbell, 1989). In fact, much sexual dysfunction in males and females can be related to neglect or abuse in childhood, including lack of sex information, sex negative attitudes, and poor family boundaries (Kinzl, Mangwerth, Traweger, & Biebl, 1996; Kinzl, Traweger, & Biebl, 1995; Sarwer & Durlak, 1996; Wilsnack, Vogeltanz, Klassen, & Harris, 1997).

As individuals learn more about natural sexual functioning, they are able to make sexual choices that foster intimacy in committed relationships. Advances in medical treatment and technology afford opportunities for all couples to realize sexual fulfillment. When there are difficulties in sexual functioning, a comprehensive evaluation, including input from both partners, is indicated. Physicians should complete a history and physical examination, including laboratory testing as indicated, to rule out disease states and medication side effects in the pathogenesis of sexual dysfunction (Kaplan, 1983; Morley & Kaiser, 1993). Urologists and gynecologists are trained generally to address male and female sexual complaints, respectively. In recent years, some physicians have devoted themselves to specialty practice in sexual medicine (Kellett, 1995; Melman et al., 1988; Verma, Khaitan, & Singh, 1998). Mental health professionals who have specialized training in sexual health are equipped to complete an assessment tailored to the particular presenting problem and the dyadic issues of the couple (Ackerman & Carey, 1995; Rosen & Leiblum, 1995; Wincze & Carey, 1991). A treatment plan that addresses organic and psychogenic etiology, including individual and relational factors, can be constructed.


TREATMENT OF SEXUAL DYSFUNCTION

Masters and Johnson (1966,1970) demystified sexual functioning and encouraged couples to seek help. Before 1970, sexual dysfunction was treated by psychiatrists and mental health professionals as symptoms of underlying emotional problems. Today, sex therapists from many disciplines, who have specialized training in the assessment and treatment of sexual problems, offer interventions which remove roadblocks to the natural expression of sexuality in an intimate relationship.

Masters and Johnson began in 1959 their revolutionary program for treating sexual problems. They worked only with couples (originally “the marital unit”) because each case of sexual dysfunction was considered relational in nature. They found that roadblocks to natural sexual functioning were primarily psychosocial (Masters & Johnson, 1970).

With advances in technology, it is clear that organic factors are frequently involved in the etiology of sexual dysfunction (Feldman, Goldstein, Hatzichristou, Krane, & McKinley, 1994; Palace, 1995). For example, vascular problems are major contributors to erectile dysfunction (Burvat et al., 1990; Rowland & Slob, 1995). However, the pioneering model of Masters and Johnson Institute never focused of the causes of individual problems. Rather, the male and female co-therapy team worked with couples to help them overcome relational and emotional roadblocks to intimacy. When intimacy is restored, the natural sexual response is facilitated. In addition, Masters and Johnson offered specific homework exercises to address particular concerns in the sexual response cycle, especially problems arising during arousal or orgasm.

The Masters and Johnson (1970) model for sex therapy involves intensive treatment of couples experiencing sexual dysfunction. Ideally, treatment is offered daily by the co-therapy team over a 2-week period (usually 10 to 12 days). Daily continuity and removal from typical distractions of work and home set the stage for optimal progress. Nevertheless, variations on the Masters and Johnson model include the “weekend intensive” and once weekly outpatient visits. The efficacy of the therapy decreases with changes from the original model, however (Masters & Johnson, 1970; Schwartz & Masters, 1988).

Although the Masters and Johnson model prescribes homework for particular types of sexual dysfunction, there are several common interventions without regard to the specific presenting problem. Initially, the couple is asked to refrain from sexual outlet. This “authoritative pronouncement” (Masters & Johnson, 1970, pp. 287-290) enables the couple to focus on intimate communication without the demand to be sexual. Another common intervention involves the “roundtable” (Masters & Johnson, 1970, pp. 57-78), in which the results of assessment are discussed and sex education is provided. The next step in intensive treatment incorporates one of the most famous interventions in the Masters and Johnson model, “sensate focus” (Masters & Johnson, 1970, pp. 66-85).

Sensate focus encourages concentration on the subtle sensations involved in intimate, nonsexual contact. Initially, the breasts and genitals are “off-limits,” fostering a sensual experience without preoccupation with sexual performance. Each partner takes turns, engaging in “selfish touching,” which is touch guided by one’s interests rather than trying to do anything to or for one’s partner. If the partner feels any discomfort or wishes to redirect the one doing the touching, then that person places his or her hand on top the partner’s hand. This “handriding” is a tool, like other techniques in the Masters and Johnson model, for realizing sexual self-responsibility. Various components of the sensate focus homework address roadblocks having to do with sexual demand, performance pressure, and “spectatoring,” or becoming an anxious observer rather than a participant in sexual functioning.

While Masters & Johnson (1970,pp. 342-360) reported success rates as high as 97% for rapid ejaculation and 80% across all male and female sexual dysfunctions, their model and research have been criticized (Reynolds, 1977; Tiefer, 1991; Zilbergeld & Evans, 1980). However, the Masters and Johnson Institute model (Masters & Johnson, 1970; Schwartz & Masters, 1988) has been for decades the guiding conceptual and clinical paradigm in sex therapy (Rosen & Leiblum, 1995). The core components of sex therapy, including nondemand sexual pleasuring, have been supported in several studies (Hawton et al., 1992; Hirst & Watson, 1997; Rosen & Leiblum, 1995; Sarwer & Durlak, 1997; Wylie, 1997).

Overall, increasing comfort and pleasure relax away anxiety previously conditioned over many frustrating sexual experiences. The sensate focus exercises, which move from nongenital exploration to nondemand sexual outlet through touch, provide opportunities to reclaim open communication and sensuality. Consultation with the couple includes recommendations for rekindling romance and enjoying intimacy.


INTERVENTIONS FOR SPECIFIC DYSFUNCTIONS

With the completion of sensate focus exercises, the couple is ready to pursue techniques targeted at specific forms of sexual dysfunction. Using the classification scheme constructed for this article (see Table), it is possible to describe some specific interventions for selected sexual dysfunctions according to phases in the sexual response cycle.


Hypoactive Sexual Desire

Hypoactive sexual desire (HSD) involves recurrent lack of sexual fantasy or interest in sexual activity. Although HSD occurs in both males and females, women most often present this dysfunction (Anderson & Cyranowski, 1995; Beck, 1995). HSD may be primary, in which a person never developed an interest in sex, or secondary to other problems or concerns. The condition may be pervasive and generalized or situational, relating only to particular partners, settings, or activities. For example, an individual may experience lack of desire for one’s partner due to suppressed anger and chronic marital discord, yet retain some sexual desire for an idyllic encounter with another person. Similarly, individuals who have atypical, especially nonpartner-oriented preferences (e.g., a paraphilia such as fetishism) may have a marked disinterest in sex with one’s available spouse (Moser, 1992). HSD must also be differentiated from medical conditions such as endocrine problems and mental disorders, including depression (Kaplan, 1979; 1983).

Following a careful differential diagnosis, it is possible to tailor treatment to the needs of the particular person. Whenever possible the partner should be included in the intervention because of the obvious relational antecedents and consequences in HSD (Heiman, Epps, & Ellis, 1995; MacPhee et al., 1995). In the typical presentation, a woman develops HSD after a long period of marital dissatisfaction. She may feel unsupported and misunderstood. Often her husband persists in making sexual demands, although they have little communication and genuine intimacy. She cannot emotionally say “Yes!” to sex because she is unable to say “No.” Her HSD develops in response to suppressed or unexpressed anger in the context of the power imbalance in the marriage (Schwartz & Masters, 1988; Southern, 1985).

Treatment involves communication and negotiation skills training for the couple (including “I language” assertion, originally developed by Virginia Johnson); sensate focus, to remove the demand for sexual outlet; and encouragement of sexual self-responsibility, by focusing upon the woman’s preferences for the marital sexual relationship (Masters & Johnson, 1970). In the more complicated cases of primary HSD, the woman will likely need a period of individual consultation to learn about sex and acquire the ability to fantasize and associate pleasure with erotic cues and sensations. In some cases, testosterone, the male sex hormone, may be prescribed to increase the female’s level of desire (Beck, 1995).


Erectile Dysfunction

Erectile dysfunction is the most common sexual problem presented in sexual medicine clinics (Kellett, 1995; Melman et al., 1988). Yet, the problem has likely persisted for some time before the anxious, performance-oriented male “acknowledges his failure” and seeks help. Sexual dysfunction and other problems of daily life are often maintained by the words and images used to describe the difficulty. The “impotent” male who has lost his masculine power becomes preoccupied with the normal variations in penile tumescence. By focusing on slight losses of erection and anticipating a “failure,” he strengthens irrational expectations and contributes to increasing anxiety, which steals the blood flow to the penis. While many cases of erectile dysfunction include organic factors (e.g., vascular disease), the syndrome of increasing performance pressure and anxious self-observation contributes significantly to the couple’s distress and avoidance (McCarthy, 1997; Masters & Johnson, 1970).

Interventions for erectile dysfunction usually include some attention to the cognitive distortions and negative self-evaluations that maintain sexual dysfunction. While it may come as a surprise to some individuals, an erect penis is not a requirement for satisfying sex. Zilbergeld (1978) delineated the “myths of male sexuality,” which are based on a hypermasculine, fantasy model of sexuality which constrains both partners. The myths that a man must orchestrate sex in which he is “hard as steel” and “lasts all night” contribute to erectile dysfunction. The initial steps in treatment for this problem include education about limitations of stereotypical gender roles and disputation of irrational beliefs concerning sexuality (Barbach, 1997; McCarthy, 1994, 1997; Zilbergeld, 1978).

Sex therapy for erectile dysfunction builds on the relaxing experience of sensate focus. By the third set of sensate focus exercises, the couple has learned that satisfying sexual outlet can be realized through genital touching in an intimate, romantic context. An erection is not needed for sexual satisfaction. Gradually, the focus is shifted to containment of the soft penis in the vagina, followed by gentle thrusting of the penis with the female astride. The therapeutic exercises are graduated to desensitize conditioned anxiety and promote sense of hope or accomplishment (Masters & Johnson, 1970).

There are several other methods for treating erectile dysfunction. Medical management includes oral medication (e.g., the long-awaited Viagra, or Sildenafil citrate, a smooth muscle relaxer), urethral suppository (MUSE or alprostadil), vacuum pump, intracavernosal injection (e.g., Caverject), vascular surgery, and penile prosthesis (Ackerman & Carey, 1995; Morley & Kaiser, 1993). Even herbal treatments such as yohimbine have been used to treat problems with erection (Guirguis, 1998). Mental health treatments include hypnotherapy, relaxation training, strategic or paradoxical intervention, and cognitive-behavior therapy. All of these methods have merit (Ackerman & Carey, 1995; Rosen & Leiblum, 1995). Needs of the particular case identified through a comprehensive assessment should determine the treatment approach. However, each case should be considered relational in nature since the partner is affected or the capacity for partner-oriented intimacy is at risk (Barbach, 1997; Read, 1995).


Rapid Ejaculation

Rapid ejaculation is a sexual dysfunction that is based clearly on relational expectations. The common term, “premature ejaculation” signifies the relational origins of a rapid climax. “Premature ejaculation” indicates that the male has climaxed before producing through intercourse an orgasm for his partner. Obviously, this perspective engenders considerable performance pressure, which in turn potentiates rapid ejaculation. This problem can be solved through a combination of cognitive therapy and therapeutic touching exercises. The intervention is tailored to the severity of the presenting problem (e.g., the most severe case involves ejaculation before intromission) (McCarthy, 1994; Masters & Johnson, 1970; Spector & Carey, 1990; Zilbergeld, 1978).

The couple learns that satisfying sex is not a linear progression from touch (sometimes called “foreplay,” implying a focus on intercourse) to mutual orgasm. Instead, either partner may experience a climax through nondemand pleasuring. In addition, the male’s ejaculation need not terminate the touching opportunity. “Start-stop touching” (also labeled “brinkmanship”) is a major intervention for treating rapid ejaculation (Zilbergeld, 1978). In this method, the male is brought to the point of ejaculatory inevitability through touch during the plateau stage of the sexual response cycle. The partner then stops stimulation, reducing the likelihood of the orgasmic reflex and providing time for the male’s relaxation. Masters and Johnson (1970) recommended the squeeze technique, in which either the corona of the glans penis or the base is squeezed by the partner to delay ejaculation.


Anorgasmia

The treatment of anorgasmia in females has some similarities with therapy for rapid ejaculation(Anderson & Cyranowski, 1995; Masters & Johnson, 1970). In both cases, there is an emphasis upon learning to recognize cues that one is moving through the plateau phase toward orgasm. In addition, individuals are encouraged to relax and assume sexual self-responsibility in touching. The anxiety-provoking demand for orgasm in intercourse is neutralized through sex education and cognitive therapy. Anorgasmia (formerly called “frigidity” in the sexist model that focused on female responsiveness to male initiation) is treated as “preorgasm” in contemporary sexual therapy (Heiman & LoPiccolo, 1988). Every woman has a right to discover and express her unique sexuality, including orgasm when she desires to have one.

Preorgasmic women learn how to facilitate sexual responses through self-touching, fantasy enhancement, and graduated desensitization exercises with a partner (Barbach, 1997; Palace, 1995). Since male-superior (”missionary position”) intercourse is not a optimal form of stimulation for most women, the preorgasmic woman and her partner experiment with other forms of stimulation, such as the use of a vibrator (Heiman & LoPiccolo, 1988). During the individual component of treatment, she is encouraged to “let go,” or experience fully the increasing excitement. One of the interventions for this component is “role play orgasm,” in which the female is asked to simulate a full-body orgasm, sometimes after viewing an instructional videotape. During the couple component of treatment, they are asked to move from sensate focus, through experimentation with various positions and forms of stimulation, to facilitation of orgasm with the partner present. When the woman is able to experience predictably her climax, then a “bridging” technique is enlisted to transfer the potential for orgasm to partner-oriented stimulation during penetration (Barbach, 1997; Heiman & LoPiccolo, 1988; Masters & Johnson, 1970).


Sexual Compulsivity

The last two types of sexual dysfunction, sexual compulsivity and vaginismus, represent relatively rare problems, frequently emerging from untreated sexual abuse trauma (Kinzl et al., 19%; Kinzl et al., 1995; Leiblum et al., 1989).The other types of dysfunction overviewed in the present article need not be caused by any underlying psychodynamics. Sexual compulsivity (also known as “sexual addiction”) is most prominent in males who have suffered sexual abuse or severe disruption of psychosexual development. The developing “lovemaps,” used by victimized males to organize their thoughts and experiences related to eroticism (Money, 1986), tend to exclude intimate, partner-oriented sexual outlet in favor of repetitive, unusual, and exploitative forms of sex. The motivation for sex is not pleasure or sensuality. Rather, the nonsexual functions of sex are exaggerated. Mood altering sexual outlet is used to manage stress, ward off depression, express anger, or bolster a fragile ego (Carnes, 1983,1996; Cooper, 1998; Schwartz, 1996).

Treating sexual compulsivity requires individual and relational interventions designed to disrupt replay of sexual trauma (Schwartz, 1996). In many cases, masturbatory excesses have conditioned variant sexual arousal. By assessing the topography or nature of the sexual arousal pattern through self-report or biofeedback (i.e., penile plethysmography), it is possible to then transfer arousal from unwanted or deviant targets to desired partner-oriented outlet (Abel, Huffman, Warberg, & Holland, 1998). Treatment also involves confronting cognitive distortions, typically in group therapy (Abel, Osborn, Anthony, & Gardos, 1992; Carnes, 1983) Other components in the treatment package involve work with the “sex addict” and the “co-addictive” partner (Schneider & Schneider, 1996). The couple examines boundaries or limits to behavior as well as family-of-origin dynamics that contribute to communication difficulty and intimacy avoidance (e.g., Carries, 1983). Sex therapy interventions are used gradually to increase vulnerability, safety, and security.


Vaginismus

The treatment of vaginismus also emphasizes the intentional facilitation of vulnerability. However, the interventions are primarily behavioral, rather than intrapsychic in nature (Read, 1995; Rosen & Leiblum, 1995). Vaginismus involves the involuntary contraction of the pelvic muscles making penetration difficult, painful, or impossible. The etiology of this condition is psychosocial, primarily in traumatic sexual experiences (Leiblum et al., 1989). Yet, “dyspareunia” or pelvic pain that is untreated conditions vaginismus as the couple continues to suffer through attempts at intercourse (Meana & Binik, 1994). Treatment of vaginismus is a microcosm of the sexual therapy model. The couple abstains from sexual outlet, engages in sensate focus or touching opportunities, learns to associate genital touching with relaxation and pleasure, and desensitizes anxieties associated with demanding, performance-oriented sexual activities. Treating vaginismus usually includes specific desensitization exercises. For example, dilators or digits of increasing circumference are introduced by the female into the vagina. Muscular tension and anxious dread are relaxed away in the safe setting afforded by sexual therapy consultation (Masters & Johnson, 1970; Read, 1995).


VIAGRA AND ERECTILE DYSFUNCTION: PROMISES AND PITFALLS

The emergence of Viagra ( Sildenafil citrate), a simple oral medication for erectile dysfunction, has generated in recent months considerable media attention, making it a good case in point for concluding remarks. Viagra produces smooth muscle relaxation and inflow of blood to the corpus cavernosum of the penis, potentiating erection when there is adequate sexual stimulation (Pfizer, 1998). It is less invasive than previous medical interventions such as surgical implantation of a penile prosthesis, injection of medication into the spongy tissue of the penis, or placement of medication via urethral suppository (Ackerman & Carey, 1995; Morley & Kaiser, 1993). Treatment of erectile dysfunction with Viagra is reasonably safe, although patients who use nitrates such as nitroglycerine could experience a hypotensive crisis (i.e., dangerously low blood pressure) if they take the medication (Pfizer, 1998).

Viagra was well tolerated in clinical trials; however, some men experienced side effects, including headache, upset stomach, visual effects (color tinge), and blurred vision (Pfizer, 1998). The side effects were so mild that few patients decided to discontinue the medication. Viagra is effective in producing erections sufficient for sexual activity in 67% to 75% of cases (Pfizer, 1998), an outcome comparable to other medical treatments and sex therapy interventions (Ackerman & Carey, 1995; Guirguis, 1998; Hawton et al., 1992; Masters & Johnson, 1970; Morley & Kaiser, 1993; Rosen & Leiblum, 1995).

Many of the 30 million men in the United States who suffer with erectile dysfunction will benefit from the increasing availability of Viagra (Pfizer, 1998). However, Viagra is not the “magic pill” or “quick fix” that some will expect or demand (Bancroft, 1990; Tiefer, 1986). Most cases of erectile dysfunction involve physical, psychosocial, and dyadic contributing factors (Burvat et al., 1990; Kaplan, 1983; Kellett, 1995; Masters & Johnson, 1966, 1970; Rosen & Leiblum, 1995). Pfizer (1998) acknowledged in its educational materials that stress, depression, performance expectations, and avoidance must be taken into consideration. Males who present psychogenic erectile dysfunction are more likely to demand rapid medical interventions that may exclude their partners (Kaplan, 1983; Masters & Johnson, 1970). Yet, effective treatment involves improving communication and enhancing intimacy with one’s partner (Barbach, 1997; Hawton et al., 1992; Masters & Johnson, 1970).

The worst case scenario for treatment with Viagra (or any medical “quick fix”) involves a physician providing samples or prescribing the medication, then sending the anxious, performance-driven male home to solve his sexual problems. Frequently, the couple has withdrawn from one another. They do not touch or even talk. The female partner may blame herself for the absence of her husband’s response or initiation. The present author is already seeing cases where the male has secretly taken Viagra, awaiting a sexual encounter that does not occur. Similarly, having the potential for erection does not insure that the partner is available or their sexual activity is satisfying. Successful treatment of erectile dysfunction and other sexual problems must involve some attention to intimacy enhancement. Pfizer (1998) included in their educational materials, which could be viewed by the male and his partner, remarks from Dr. Gerald R. Weeks, a marital and sex therapist. Dr. Weeks (Pfizer, 1998, pp. 9-11) recommended some activities for improving the relationship and enhancing intimacy. In referring to the roadblocks to sexual health, he noted, “no treatment for ED will make these barriers magically disappear” and “Your relationship needs to be a priority at times” (Pfizer, 1998, p. 11).

Safe, effective medical interventions such as treatment of erectile dysfunction with Viagra remove roadblocks to natural sexual functioning and create opportunities to reclaim intimacy in relationships. Use of Viagra will be the beginning of a process intended to cultivate emotional and physical closeness in thousands of couples, not the end of an anxiety-driven pursuit to remove a sexual symptom. Although sex therapy lacks definitive research findings and well-established theory (Reynolds, 1977; Rosen & Leiblum, 1995; Weis, 1998), the classic model of Masters and Johnson (1966,1970), with its emphasis on nonsexual touching and open communication, promises to help the field go back to the future.

Technological advances in the 1990s have facilitated careful assessment and reliable treatment for most cases of sexual dysfunction. Specific interventions have been developed for particular types of dysfunction. However, sexual problems evolve in the relational context. Conditioned anxiety, performance pressure, and sexual misconception are common among couples who present for treatment. They would like to regain the natural sexual function. They would also like to enhance the communication and romance in their relationship. Assessment and treatment of sexual dysfunctions should begin with medical examination. Then, sex therapy interventions offered by skilled clinicians can restore intimacy, while removing psychosocial roadblocks to optimal sexual functioning.

Sigusch (1998) discussed a neosexual revolution in which diversification in intimate relationships overcomes the banalization, dissociation, and medicalization of sexuality. Hacker (1990) described a transition from the old norms to the new sexual values of the 1990s in which pleasuring, without the demand for intercourse, heralds a path to caring, respectful behavior between men and women. Perhaps D.H. Lawrence best captured the heart of the “new” sexual health emphasis upon intimacy enhancement in his poem “Wedlock” (de Sola Pinto & Roberts, 1978).

How I love all of you! Do you feel me wrap you
Up with myself and my warmth, like a flame round the wick?
... I spread over you! How lovely your round head, your arms,
Your breasts, your knees and feet! I feel that we
Are a bonfire of oneness, me flame flung leaping round you,
You the core of the fire, crept into me. (p. 245)


Types of Dysfunction by Phase in the Sexual Response Cycle

Legend for Chart: 
	
A - Phase
B - Types of Dysfunction Male
C - Types of Dysfunction Female 
	
A
  B
    C 
	
Desire
  Hypoactive Sexual Desire
  Sexual Aversion
  Sexual Desire Discrepancy
  Sexual Compulsivity
  Paraphilia
    Hypoactive Sexual Desire
    Sexual Aversion
    Sexual Desire Discrepancy
    Sexual Compulsivity
    Paraphilia 
	
Arousal
  Erectile Dysfunction
    Sexual Arousal Disorder 
	
Orgasm
  Delayed Ejaculation
  Rapid Ejaculation
    Anorgasmia 
	
Resolution
  Sexual Compulsivity
  Intimacy Dysfunction
    Sexual Compulsivity
    Intimacy Dysfunction 
	
Pain[*]
  Dyspareunia
    Dyspareunia
    Vaginismus 
	
[*] Pain may occur in several phases, although these conditions
are frequently encountered during attempts at penetration.


REFERENCES

Ackerman, M. D., & Carey, M. P. (1995). Psychology’s role in the assessment of erectile dysfunction: Historical precedents, current knowledge, and methods. Journal of Consulting and Clinical Psychology, 63, 862-876.

Abel, G. G., Huffman, J., Warberg, B., & Holland, C. L. (1998). Visual reaction time and plethysmography as measures of sexual interest in child molesters. Sexual Abuse: Journal of Research and Treatment, 10, 81-95.

Abel, G. G., & Osborn, C. (1992). The paraphilias: The extent and nature of sexually deviant and criminal behavior. Psychiatric Clinics of North America, 15, 675-687.

Abel, G. G., Osborn, C. A., Anthony, D., & Gardos, P. (1992). Current treatment of paraphiliacs. Annual Review of Sex Research, 3, 255-290.

Abel, G., & Roleau, J. L. (1995). Sexual abuses. Psychiatric Clinics of North America, 18, 139-153.

American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.

Anderson, B. L., & Cyranowski, J. M. (1995). Women’s sexuality: Behaviors, responses, and individual differences. Journal of Consulting and Clinical Psychology, 63, 891-906.

Apfelbaum, B. (1989). Retarded ejaculation: A much-misunderstood syndrome. In S. R.

Leiblum & R. C. Rosen (Eds.), Principles and practice of sex therapy: Update for the 1990s (pp. 168-206). New York: Guilford Press.

Ashton, A. K., Hamer, R., & Rosen, R. C. (1997). Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: A large-scale retrospective study of 596 psychiatric outpatients. Journal of Sex and Marital Therapy, 23, 165-175.

Bancroft, J. (1990). Man and his penis: A relationship under threat? Journal of Psychology and Human Sexuality, 2, 6-32.

Barbach, L. (1997). Loving together: Sexual enrichment program. Bristol, PA: Brunner/Mazel.

Beck, J. G. (1995). Hypoactive sexual desire: An overview. Journal of Consulting and Clinical Psychology, 63, 919-927.

Burvat, J., Burvat-Herbaut, M., Lemaire, A., Marcolin, G., & Quittelier, E. (1990). Recent developments in the clinical assessment and diagnosis of erectile dysfunction. Annual Review of Sex Research, 1, 265-308.

Byrne, D., & Schulte, L. (1990). Personality dispositions as mediators of sexual responses. Annual Review of Sex Research, 1, 93-117.

Carnes, P. (1983). Out of the shadows: Understanding sexual addiction. Minneapolis, MN: Compcare.

Carnes, P. J. (1996). Addiction or compulsion: Politics or illness? Sexual Addiction and Compulsivity, 3, 127-150.

Cooper, A. (1998). Sexually compulsive behavior. Contemporary Sexuality, 32, 1-3.

de Sola Pinto, V., & Roberts, E W. (1978). D. H. Lawrence: The complete poems. New York: Penguin Books

Feldman, H. A., Goldstein, I., Hatzichristou, D. G., Krane, R. J., & McKinley, J. B. (1994). Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. Journal of Urology, 151, 54-61.

Guirguis, W. (1998). Oral treatment of erectile dysfunction: From herbal remedies to designer drugs. Journal of Sex and Marital Therapy, 24, 69-73.

Hacker, S. S. (1990). The transition from the old norm to the new: Sexual values for the 1990s. SIECUS Report, 18, 1-8.

Hawton, K., Catalan, J., & Fagg, J. (1992). Sex therapy for erectile dysfunction: Characteristics of couples, treatment outcome, and prognostic factors. Archives of Sexual Behavior, 21, 161-175.

Heiman, J. R., Epps, P. H., & Ellis, B. (1995). Treating sexual desire disorders in couples. In N. S. Jacobson & A. S. Gurman (Eds.), Clinical handbook of couple therapy (pp. 471-495). New York: Guilford.

Heiman, J. R., & LoPiccolo, L. (1988). Becoming orgasmic: A sexual growth program for women. New York: Prentice Hall.

Hirst, J. F., & Watson, J. P. (1997). Therapy for sexual and relationship problems: The effects on outcome of attending as an individual or as a couple. Sexual and Marital Therapy, 12, 321-337.

Kaplan, H. S. (1979). Disorders of sexual desire. New York: Brunner/Mazel.

Kaplan, H. S. (1983). The evaluation of sexual disorders: Psychological and medical aspects. New York: Brunner/Mazel.

Kellett, J. (1995). Functions of a sexual dysfunction clinic. International Review of Psychiatry, 7, 183-190.

Kinzl, J. F., Mangwerth, B., Traweger, C., & Biebl, W. (1996). Sexual dysfunctions in males: Significance of adverse childhood experiences. Child Abuse and Neglect, 20, 759-766.

Kinzl, J. F., Traweger, C., & Biebl, W. (1995). Sexual dysfunctions: Relationship to childhood sexual abuse and early family experiences in a nonclinical sample. Child Abuse and Neglect, 19, 785-792.

Leiblum, S. R., Pervin, L. A., & Campbell, E. H. (1989). The treatment of vaginismus: Success and failure. In S. R. Leiblum & R. C. Rosen (Eds.), Principles and practice of sex therapy: Update for the 1990s (pp. 113-140). New York: Guilford Press.

Lobitz, W. C., & Lobitz, G. K. (1996). Resolving the sexual intimacy paradox: A developmental model for the treatment of sexual desire disorders. Journal of Sex and Marital Therapy, 22, 71-84.

McCabe, M. P. (1997). Intimacy and quality of life among sexually dysfunctional men and women. Journal of Sex and Marital Therapy, 23, 276-290.

McCabe, M. P., & Cobain, M. J. (1998). The impact of individual and relationship factors on sexual dysfunction among males and females. Sexual and Marital Therapy, 13, 131-143.

McCarthy, B. W. (1994). Etiology and treatment of early ejaculation. Journal of Sex and Marital Therapy, 20, 5-6.

McCarthy, B. W. (1997). Chronic sexual dysfunction: Assessment, intervention, and realistic expectations. Journal of Sex Education and Therapy, 22, 51-56.

MacPhee, D. C., Johnson, S. M., & van der Veer, M. M. C. (1995). Low sexual desire in women: The effects of marital therapy. Journal of Sex and Marital Therapy, 21,159-182.

Masters, W. H., & Johnson, V. E. (1966). Human sexual response. Boston, MA: Little, Brown & Co.

Masters, W. H., & Johnson, V. E. (1970). Human sexual inadequacy. New York: Bantam Books.

Meana, M., & Binik, Y. M. (1994). Painful coitus: A review of female dyspareunia. Journal of Nervous and Mental Disease, 182, 264-272.

Melman, A., Tiefer, L., & Pedersen, R. (1988). Evaluation of the first 406 patients in a urology department based center for male sexual dysfunction. Urology, 32, 6-10.

Money, J. (1986). Lovemaps. New York: Irvington Publishers.

Moret, L. B., Glaser, B. A., Page, R. C., Bargeron, E. F. (1998). Intimacy and sexual satisfaction in unmarried couple relationships: A pilot study. The Family Journal: Counseling and Therapy for Couples and Families. 6, 33-39.

Morley, J. E., & Kaiser, F. E. (1993). Impotence: The internist’s approach to diagnosis and treatment. Advances in Internal Medicine, 38, 151-168.

Moser, C. (1992). Lust, lack of desire, and paraphilias: Some thoughts and possible connections. Journal of Sex and Marital Therapy, 18, 65-69.

Palace, E. M. (1995). A cognitive-physiological process model of sexual arousal and response. Clinical Psychology: Science and Practice, 2, 370-384.

Pfizer. (1998,May). The new facts of life. [Videotape and brochure, HX728F97]. (Available from Pfizer U.S. Pharmaceuticals, 235 East 42nd St., New York, NY 10017-5755).

Read, J. (1995). Female sexual dysfunction. International Review of Psychiatry, 7(2), 175-182.

Renshaw, D. C. (1988). Profile of 2,376 patients treated at Loyola Sex Clinic between 1972 and 1987. Sexual and Marital Therapy, 3, 111-117.

Reynolds, B. S. (1977). Psychological treatment models and outcome results for erectile dysfunction. Psychological Bulletin, 84, 1218-1238.

Rosen, R. C., & Leiblum, S. R. (1995). Treatment of sexual disorders in the 1990s: An integrated approach. Journal of Consulting and Clinical Psychology, 63, 877-890.

Rowland, D. L., & Slob, A. K. (1995). Understanding and diagnosing sexual dysfunction: Recent progress through psychophysiological and psychophysical methods. Neuroscience and Biobehavioral Review, 19, 201-209.

Sarwer, D. B., & Durlak, J. A. (1996). Childhood sexual abuse as a predictor of adult female sexual dysfunction: A study of couples seeking sex therapy. Child Abuse and Neglect, 20, 963-972.

Sarwer, D. B., & Durlak, J. A. (1997). A field trial of the effectiveness of behavioral treatment for sexual dysfunction. Journal of Sex and Marital Therapy, 23, 87-97.

Schnarch, D. (1997). Passionate marriage: Sex, love, and intimacy in emotionally committed relationships. New York: W.W. Norton.

Schneider, J. P., & Schneider, B. H. (1996). Couple recovery from sexual addiction/compulsivity: Results of a survey of 88 marriages. Sexual Addiction and Compulsivity, 3, 111-126.

Schwartz, M. F. (1996). Reenactment related to bonding and hypersexuality. Sexual Addiction and Compulsivity, 3, 195-212.

Schwartz, M. F., & Masters, W. H. (1988). Inhibited sexual desire: The Masters and Johnson Institute treatment model. In S. R. Leiblum & R. C. Rosen (Eds.), Sexual desire disorders. (pp. 229-242). New York: Guilford Press.

Seagraves, R. T. (1998). Antidepressant-induced sexual dysfunction. Journal of Clinical Psychiatry, 59, 48-54

Sigusch, V. (1998). The neosexual revolution. Archives of Sexual Behavior, 27, 331-359.

Southern, S. (1985). Hypoactive sexual desire: A cognitive model. Journal of Sex Education and Therapy, 11, 55-60.

Spector, I. P., & Carey, M. P. (1990). Incidence and prevalence of the sexual dysfunctions: A critical review of the empirical literature. Archives of Sexual Behavior, 19, 389-408.

Steege, J. F., & Ling, F. W. (1993). Dyspareunia: A special type of chronic pelvic pain. Obsterics and Gynecology Clinics of North America, 20, 779-793.

Tiefer, L. (1986). In pursuit of the perfect penis: The medicalization of male sexuality. American Behavioral Scientist, 29, 579-599.

Tiefer, L. (1991). Historical, scientific, clinical and feminist criticisms of “the human sexual response cycle” model. Annual Review of Sex Research, 2, 1-23.

Verma, K. K., Khaitan, B. K., & Singh, O. P. (1998). The frequency of sexual dysfunctions in patients attending a sex therapy clinic in North India. Archives of Sexual Behavior, 27, 309-314.

Weis, D. L. (1998). Conclusion: The state of sexual theory. Journal of Sex Research, 35, 100-114.

Whipple, B., Gerdes, C. A., & Komisaruk, B. R. (1996). Sexual response to self-stimulation in women with complete spinal cord injury. Journal of Sex Research, 33, 231-240.

Wilsnack, S. C., Vogeltanz, N. D., Klassen, A. D., & Harris, T. R. (1997). Childhood sexual abuse and women’s substance abuse: National survey findings. Journal of Studies on Alcoholism, 58, 264-271.

Wincze, J. P., & Carey, M. P. (1991). Sexual dysfunction: A guide for assessment and treatment. New York: Guilford Press.

Woody, J. D., & D’Souza, H. J. (1997). Sexual interaction in nonclinical couples. The Family J

KAISER MUST PROVIDE SILDENAFIL COVERAGE IN CALIFORNIA

September 8th, 2007

Title: KAISER MUST PROVIDE SILDENAFIL COVERAGE IN CALIFORNIA ,  Urology Times, 00939722, Mar99, Vol. 27, Issue 3

Section: In Brief

The Kaiser Foundation Health Plan cannot exclude sildenafil citrate (Viagra) and other drugs treating sexual dysfunction from coverage in California, according to a ruling by the state’s Department of Corporations. However, the ruling does allow the plan to charge enrollees half the cost of such drugs.

Kaiser, the largest non-profit HMO in the U.S. with 8.3 million members, has received permission to exclude coverage of the drugs from the District of Columbia and 12 other states. Two-thirds of the plan’s members reside in California.


Copyright of Urology Times is the property of Advanstar Communications Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Urology Times, Mar99, Vol. 27 Issue 3, p3, 1p

NIH PANEL: IMPOTENCE IS OFTEN TREATABLE IN OLDER MEN

September 8th, 2007

Title: NIH PANEL: IMPOTENCE IS OFTEN TREATABLE IN OLDER MEN ,  Geriatrics, 0016867X, Sep93, Vol. 48, Issue 9

Section: WHAT’S NEW

Latest news in geriatric medicine

Impotence is often a treatable condition in older men and should not be considered a natural consequence of aging, even though the risk for erectile dysfunction increases with age, a National Institutes of Health panel concludes.

In a recently released report, the panel outlines several diagnostic and treatment guidelines for erectile dysfunction. Among their recommendations:

  • In men complaining of erectile dysfunction, conduct a detailed medical and sexual history, followed by physical examination and basic laboratory studies to identify potential psychological factors as well as unrecognized disease.
  • Include in the physical exam the testicles, penis, prostate, anal sphincter tone, femoral and lower extremity pulses, and neurologic examination of perianal sensation and bulbocavernosus reflex.
  • Conduct urinalysis and blood tests for complete blood count, creatinine, lipid profile, fasting blood sugar, thyroid function, and morning testosterone.
  • Consider intracavernous injection of a vasodilating agent to assess penile blood, but limit this procedure to patients who are seriously considering penile injections, implants, or vascular surgery.
  • Consider IM testosterone enanthate or cypionate for patients with confirmed low serum testosterone. Oral bromocryptine is recommended for patients with confirmed hyperprolactinemia. If testicular function is normal, however, such treatments increase the risk for prostate cancer.
  • Include the patient’s sexualpartner in the evaluation and treatment, if possible. Counseling is always recommended.

Copyright of Geriatrics is the property of Advanstar Communications Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Geriatrics, Sep93, Vol. 48 Issue 9, p31, 1p

IS NASAL VIAGRA A REASON TO GET EXCITED?

September 8th, 2007

Title: IS NASAL VIAGRA A REASON TO GET EXCITED? ,  By: David, Grainger, Fortune, 00158259, 2/18/2002, Vol. 145, Issue 4

Section: First

Medicine

Bob Dole needs a new job. After being fired by Viagra for being too old, the first ambassador of erectile dysfunction may now be in luck: A barrage of new impotence treatments are expected to hit pharmacies in the next two years, and marketing will be central to their success.

If things look good for Dole, they look even better for the 30 million American men with erectile dysfunction (ED, in the industry vernacular). For the first time drugmakers are offering a wide range of alternatives to the little blue pill, everything from Viagra me-toos to nasal sprays. Sales of ED drugs are expected to more than double in the next two years, from roughly $2 billion in 2002 to more than $4 billion by 2004. Viagra’s maker, Pfizer, currently owns about 90% of that market, but”Watch yourself.” Of the 30 million men who have ED, only 1.7 million fill prescriptions regularly, according to Dr. William D. Steers at the University of Virginia. “These new drugs pose a big threat to Viagra,” says Chrystyna Bedrij, who covers the ED market at Griffin Securities.

One of the most interestingnew treatments for ED is a topical cream from NexMed, a small biotech outfit in Robbinsville, N.J. NexMed will likely be the first cream ED treatment available by prescription in the pill-dominated marketplace. To some, the first ED topical cream may sound as appealing as the first ketchup Popsicle to hit the frozen-food section, but it could fill an important need: “This drug is for people who have tried Viagra, and it doesn’t work,” says Bedrij. Don’t scoff: Severe cases make up 30% of the ED market, which leaves plenty of market for drugs that create, as Dr. Steers says, “an erection that is almost automatic.”

NexMed’s cream works (it’s called Alprox-TD) by delivering the generic drug alprostadil in a tiny (0.1 ml), colorless, odorless drop with a disposable applicator. Alprostadil, you may remember, is the same mojo that was injected (yes, with a needle) into the nether regions of the first ED patients. To work, the cream must actually penetrate the tissue and enter the bloodstream (some doctors aren’t convinced; the drug is currently in late stages of testing, and has yet to be reviewed by the FDA).

Leading the pack of more traditional treatments are two pills that will challenge Viagra. These me-too drugs are Vardenafil, from Bayer, and Cialis, from Icos-LillyBayer says the drug will be the first ED pill that’s safe for diabetes patients. Cialis has been touted as the “weekend drug” for its potential 24-hour effectiveness, as opposed to four hours for Viagra.

What all this means to you, of course, is loads of new sales pitches. For a breakdown of everything on the horizon, from Uprima (a European Union-approved drug that works on the brain) to Nastech (the company developing that nasal spray), see our table and rankings. Somehow we just couldn’t get behind that nasal-spray concept. At least, you know, until Bob Dole does.


	

PRODUCT/AVAILABILITY THE SCOOP THE DOLE RATING

Alprox-TD The first topical cream, it X X X

2003 works in 10 to 20 minutes and

is good for severe cases of ED.

Cialis The “weekend drug” stays in X X X X

2002 the body up to 24 hours–great

for getaways, but could heighten

side effects.

Nasal apomorphine Nasal spray is in development, X

2004 but will you confuse it with

cold medication?

Uprima Don’t bother trying to get X X

N.A. in U.S. Uprima in the U.S.; the FDA

rejected the drug, which works

on the brain. The success rate

is lower than other ED

treatments.

Vardenafil Faster acting and longer lasting X X X X X

2002 than Viagra, the drug has few

side effects and is safe for

diabetics.

~~~~~~~~

By Grainger David


Copyright of Fortune is the property of Time Inc. and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Fortune, 2/18/2002, Vol. 145 Issue 4, p28, 2p

There is help for men who experience E.D.

September 8th, 2007

Title: There is help for men who experience E.D. ,  By: Pinette, Gilles, Windspeaker, 0834177X, Dec2003, Vol. 21, Issue 9

Section: strictly speaking



MEDICINE BUNDLE

More than 50 per cent of men over the age of 40 will have problems with erections at some time. The problem becomes more common as men age.

Erectile dysfunction (E.D.) is a medical term that describes when a man has difficulty getting and maintaining an erection that allows him to have satisfactory intercourse. While E.D. is common, many men still do not discuss this matter with their family physician. Understandably, men may be embarrassed by E.D., but hopefully public education by well-known people, such as Guy LaFleur, will help to make it easier to address.


How does E.D. occur?

Erections can occur when a man is stimulated by something they see, smell, hear, taste, feel, imagine, or remember. The stimulus causes special interactions in the brain and the nerves in the penis which allow an erection to occur. The penis becomes erect when blood flow into the penis is trapped temporarily, causing the penis to enlarge and become harder. The penis becomes flaccid again when the veins open up and allow the blood flow to drain from the penis.

Anxiety, tension, guilt, depression, and lack of self-confidence can contribute to E.D. Tension or conflict between sexual partners is a common cause (e.g., arguments, financial or marital problems). These factors work at the brain level to interfere with erections.

When blood flow is affected by heart or blood vessel disease, high blood pressure, high cholesterol levels, diabetes, or by cigarette smoking, it can lead to E.D. Other causes include thyroid disease, spinal cord injuries, disorders of the testicles, and certain kinds of prescription medications. Drinking alcohol or using illegal drugs can cause E.D. as well.


What now?

A man with E.D. should discuss his symptoms with his family doctor. After reviewing the medical history and conducting a physical exam, your doctor may order some blood tests to investigate for any possible medical cause.


Solutions

The first step is removing anything that might interfere with your erection. Stop smoking, treat medical problems, minimize alcohol drinking, and problem-solve conflicts in your life. Counseling may be helpful as well.

Several medications have been used to get and keep erections. Yohimbine is a bark extract from the African yohimbe tree that can sometimes help stimulate erections.

Some medications have been very successful in causing erections but may require more work-injecting the medication at the base of the penis or inserting a tiny dose of medicine into the end of the penis with a special applicator.

The most popular medication prescribed for E.D. today is sildenafil (i.e., Viagra). It is widely used because it helps about 70 per cent of men with E.D. get erections. Soon there will be a few new E.D. medications on the market.

Non-medication treatments can be used. A special vacuum pump can be used to create an erection and then a rubber constriction band is placed at the base of the penis to keep the blood from flowing out.

Surgical choices include the implantation of either a rod-like device or an inflatable pump-up device within the penis. These implants can make the penis functional for sexual intercourse.

Remember, all medications and treatments have pros and cons. The first step is to talk to your doctor.

The author assumes no responsibility or liability arising from any outdated information, errors, omissions, claims, demands, damages, actions, or causes of actions from the use of any of the above information.

PHOTO (BLACK & WHITE)

~~~~~~~~

By Gilles Pinette


Copyright of Windspeaker is the property of Aboriginal Multi-Media Society and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Windspeaker, Dec2003, Vol. 21 Issue 9, p18, 1p

DEPRESSION AND SEXUAL DESIRE

September 8th, 2007

Title: DEPRESSION AND SEXUAL DESIRE ,  By: Phillips Jr., Robert L., American Family Physician, 0002838X, 08/15/2000, Vol. 62, Issue 4


Decreased libido disproportionately affects patients with depression. The relationship between depression and decreased libido may be blurred, but treating one condition frequently improves the other. Medications used to treat depression may decrease libido and sexual function. Frequently, patients do not volunteer problems related to sexuality, and physicians rarely ask about such problems. Asking a depressed patient about libido and sexual function and tailoring treatment to minimize adverse effects on sexual function can significantly increase treatment compliance and improve the quality of the patient’s life. (Am Fam Physician 2000;62:782-6.)

Symptomatic loss of libido is a common problem in the United States. In a national survey conducted in 1994, 33 percent of women and 17 percent of men reported sexual disinterest.(n1) In another survey, one third of women 18 to 59 years of age reported feeling a lack of sexual desire within the previous year.(n2) Patients with major depressive disorder or bipolar disorder have an even higher prevalence of sexual dysfunction, including lowered libido, than the general population.(n3)

In one study it was found that more than 70 percent of depressed patients had a loss of sexual interest when not taking medication, and they reported that the severity of this loss of interest was worse than the other symptoms of depression.(n4) In this same study, libido declined with increasing severity of psychologic illness. The complex association between depression and lowered libido is further illustrated in a case control study in which increased lifetime prevalence rates of affective disorder were found among patients with inhibited sexual desire.(n5)

Regardless of the cause-and-effect relationship, depression and decreased libido are associated, and the treatment of one condition may improve the other. This article focuses on decreased libido associated with depression, the effects of treatment of depression on libido, and the effects of changes in libido and sexual functioning on compliance.


Discussing Libido

Patients have difficulty discussing sexual dysfunction (decreased libido, erectile dysfunction and anorgasmia) and acknowledging decreased libido may be particularly difficult. Patients under-report sexual problems caused by medications.(n6,n7) They may acknowledge a decline in libido only if their partner complains. Even when a declining interest in sex is recognized, it may be rationalized on the basis of social values and practices, especially among aging women.(n8) Discovery of sexual problems is further limited by the frequent failure of physicians to ask about such problems.(n9) The latter point is critical: in one study it was found that patients taking selective serotonin reuptake inhibitors (SSRIs) were four times more likely to reveal sexual dysfunction if asked directly by their physician.(n7)

It is important to get baseline information about sexual dysfunction, including lowered libido, to accurately assess the effects of treatment. The authors have found that placing libidinal effects in the context of the patient’s general interests and activities avoids suggestion and excessive preoccupation, but allows adequate assessment before and after treatment is initiated.


Other Issues Affecting Libido

Patients whose depression improves with treatment but who continue to experience a lowered libido should be asked about their use of other medications. Several antipsychotic agents, including haloperidol (Haldol), thioridazine (Mellaril) and risperidone (Risperdal) can decrease libido.(n9,n10) Cimetidine (Tagamet), in contrast to ranitadine (Zantac), has been found to lower libido and cause erectile dysfunction.(n11)

Women in their late reproductive years who take oral contraceptives and postmenopausal women who are given estrogen replacement therapy may experience an improvement of depressive symptoms but a lowering of libido.(n12) Libido lowering is attributed to estrogen-induced deficiency of free testosterone.(n12,n13) Testosterone testing and supplementation should be considered in women who experience a decline in libido after starting estrogen therapy.(n14) Testosterone testing should also be considered in men who have a gradual loss of libido and no improvement despite adequate treatment for depression.(n15)

It is important to assess the patient for psychologic and interpersonal factors that commonly affect depression and sexual desire. These factors include stressful life events (loss of job or family trauma), life milestones (children leaving home) and ongoing relationship problems.(n16)

Alcohol and narcotics are known to decrease libido, arousal and orgasm.(n17) Because the use of alcohol and other drugs is more common in patients with psychologic disorders, alcohol and drug abuse should be considered when investigating libido problems in patients with depression.


Lowered Libido After Treatment

Consistent evidence shows that, with the exception of bupropion (Wellbutrin), trazodone (Desyrel) and nefazodone (Serzone), antidepressant medications may cause a decline in libido or sexual functioning despite improvement of depression.(n18) Up to one half of patients surveyed before and after starting therapy with the SSRIs fluoxetine (Prozac), paroxetine (Paxil), fluvoxamine (Luvox), citalopram (Celexa) and sertraline (Zoloft) reported a decline in libido with medication use.(n7) SSRIs also cause other sexual dysfunction that can affect libido and compliance.(n19,n20)

In a double-blind clinical trial of treatment with imipramine (Tofranil), phenelzine (Nardil) or placebo, it was found that 30 to 40 percent of patients taking either antidepressant reported a decline in sexual desire, while 6 percent of those taking placebo experienced the same effect.(n21) Although the use of monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants to treat depression is on the decline, tricyclic agents are increasingly being prescribed for control of pain. When tricyclics are prescribed for pain, it is not uncommon for them to be used in conjunction with SSRIs. SSRIs increase serum levels of tricyclics, so this combination may affect libido more than either alone. Table 1 summarizes the effects of various antidepressants and antipsychotics on libido.


MANAGEMENT

When libido remains low after depression has been treated, the other issues discussed above should be considered. When decreased libido begins or worsens after a patient starts taking antidepressant medications, it is important to address the problem without compromising the treatment of the depression. Failure to deal with the sexual problem may result in treatment noncompliance.(n22)

Several options exist for managing medication-induced sexual dysfunction (Figure 1). Decreasing the dosage of the antidepressant may improve libido while maintaining adequate treatment of depression. In one study, 73 percent of patients whose SSRI dosage was halved reported improved sexual function while antidepressant effectiveness continued.(n7) This dosage effect has also been found for SSRIs and imipramine in other studies.(n21,n23,n24) The only evidence about drug holidays comes from a small, open study in which findings suggest that one- to two-day holidays from the shorter half-life SSRIs (i.e., sertraline, paroxetine) may be helpful. This effect did not apply to fluoxetine.(n25)

If a reduction in the antidepressant dosage does not maintain adequate treatment of depression, other options are to add a medication and change the medication. In studies comparing bupropion with sertraline and placebo, patients treated with bupropion experienced improvement in libido.(n26) There is good evidence that treatment with bupropion raises libido above predepression levels.(n27) In less rigorous studies, improvement of libido with a change to bupropion or the addition of bupropion to existing medications was found.(n28,n29) Patients who switched from sertraline to nefazodone in a double-blind clinical trial reported that their libido returned to baseline levels.(n30)


PSYCHIATRIC THERAPY FOR DISORDERS OF SEXUAL DESIRE

Psychotherapy has variable effects for depression-related problems of sexual desire.(n31) Better outcomes are associated with the absence of life-long or global desire disorders and with strong relationships.(n16) In a review of published studies regarding psychotherapy for sexual dysfunction, it was found that in nearly 80 percent of the published reports the research was of poor quality and that no treatment was consistently useful.(n32)


Final Comment

Decreased libido affects many patients but disproportionately affects patients with depression. There is evidence that the decline in libido is related to the depth of depression. It is important to get baseline information regarding libido and sexual function before initiating treatment for depression. It is also important to assess patients’ libido and sexual functioning after starting antidepressant therapy, as patients may be reluctant to report difficulties.

If treating the depression does not improve libido, other causes of sexual dysfunction should be considered, such as hormone deficiencies, chronic disease, drug and alcohol abuse, or use of other medications. Evidence supports several treatment options in patients who experience sexual dysfunction or decreased libido as a consequence of antidepressant use. These include decreasing the dosage of an SSRI or tricyclic antidepressant, instigating medication holidays, adding or switching to bupropion, and using nefazodone as an alternative agent. Cause and effect may not be clear, but addressing sexual desire when treating depression may improve compliance and overall outcome.

The authors thank Robert L. Blake, M.D., for assistance with the manuscript.

Dr. Slaughter was not sponsored directly or indirectly to prepare the manuscript. Moreover, neither he nor any immediate family member has a financial interest or arrangement with any organization that may have a direct interest in the subject matter of this article, except as follows: Dr. Slaughter has received speaker honoraria and research support from Pfizer Pharmaceuticals, SmithKline Beecham, Wyeth Laboratories, and Eli Lilly and Co.

Address correspondence to Robert L. Phillips, Jr., M.D., Dept. of Family and Community Medicine, University of Missouri-Columbia, MA303 Health Sciences Center, Columbia, MO 65212. Reprints are not available from the authors.


TABLE 1 Effects on Libido of Various Antidepressants and Other Medications

Legend for Chart: 
	
A - Medication
B - Libido effect
C - Other sexual effects 
	
            A                  B                C 
	
SSRIs 
	
Fluoxetine (Prozac),       Decrease    Anorgasmia, delayed
paroxetine (Paxil),                    ejaculation, erectile
fluvoxamine (Luvox),                   dysfunction
citalopram (Celexa),
sertraline (Zoloft) 
	
Imipramine (Tofranil),     Decrease    Erectile dysfunction
phenelzine (Nardil) 
	
Bupropion (Wellbutrin)     Increase    None 
	
Trazodone (Desyrel)        Increase    Priapism (rare) 
	
Nefazodone (Serzone)       No change   None 
	
Antipsychotics 
	
Haloperidol (Haldol),      Decrease    Anorgasmia, erectile
thioridazine (Mellaril),               dysfunction, painful
risperidone (Risperdal)                ejaculation 
	
SSRIs = selective serotonin reuptake inhibitors. 
	
Information from references 7, 9, 10, and 18 through 21.

DIAGRAM: FIGURE 1. Algorithm for managing medication-induced sexual dysfunction. (SSRI = selective serotonin reuptake inhibitor)


REFERENCES

(n1.)
Michael RT. Sex in America: a definitive survey. Boston: Little, Brown, 1994.

(n2.)
Laumann EO. The social organization of sexuality: sexual practices in the United States. Chicago: University of Chicago Press, 1994.

(n3.)
Segraves RT. Psychiatric illness and sexual function. Int J Impot Res 1998;10(suppl 2):S131-3,S138-40.

(n4.)
Casper RC, Redmond DE, Katz MM, Schaffer CB, Davis JM, Koslow SH. Somatic symptoms in primary affective disorder. Presence and relationship to the classification of depression. Arch Gen Psychiatry 1985;42:1098-104.

(n5.)
Schreiner-Engel P, Schiavi RC. Lifetime psychopathology in individuals with low sexual desire. J Nerv Ment Dis 1986;174:646-51.

(n6.)
Monteiro WO, Noshirvani HF, Marks IM, Lelliott PT. Anorgasmia from clomipramine in obsessive-compulsive disorder. A controlled trial. Br J Psychiatry 1987;151:107-12.

(n7.)
Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calcedo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94.

(n8.)
Kingsberg SA. Postmenopausal sexual functioning: a case study. Int J Fertil Womens Med 1998; 43:122-8.

(n9.)
Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: the unspoken side effect of antipsychotics. European Psychiatry 1998;13(suppl 1):23s-30s.

(n10.)
Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999;156:631-3.

(n11.)
Zimmerman TW. Problems associated with medical treatment of peptic ulcer disease. Am J Med 1984;77:51-6.

(n12.)
Nathorst-Boos J, von Schoultz B, Carlstrom K. Elective ovarian removal and estrogen replacement therapy–effects on sexual life, psychological well-being and androgen status. J Psychosom Obstet Gynaecol 1993;14:283-93.

(n13.)
Davis SR, Burger HG. Use of androgens in postmenopausal women. Curr Opin Obstet Gynecol 1997;9:177-80.

(n14.)
Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47:339-51.

(n15.)
Bagatell CJ, Bremner WJ. Androgens in men–uses and abuses. N Engl J Med 1996;334:707-14.

(n16.)
Heiman JR, Meston CM. Evaluating sexual dysfunction in women. Clin Obstet Gynecol 1997; 40:616-29.

(n17.)
Miller NS, Gold MS. The human sexual response and alcohol and drugs. J Subst Abuse Treat 1988; 5:171-7.

(n18.)
Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol 1997;11:72-82.

(n19.)
Segraves RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry 1998;59(suppl 4):48-54.

(n20.)
Michael A, Herrod JJ. Citalopram-induced decreased libido [Letter]. Br J Psychiatry 1997;171:90.

(n21.)
Harrison WM, Rabkin JG, Ehrhardt AA, Stewart JW, McGrath PJ, Ross D, et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986;6:144-9.

(n22.)
Harvey KV, Balon R. Clinical implications of antidepressant drug effects on sexual function. Ann Clin Psychiatry 1995;7:189-201.

(n23.)
Benazzi F, Mazzoli M. Fluoxetine-induced sexual dysfunction: a dose-dependent effect? Pharmacopsychiatry 1994;27:246.

(n24.)
Clinical management of depression: bupropionAn Update Meeting,” held in Boca Raton, Fla., October 30-31, 1992.

(n25.)
Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-6.

(n26.)
Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987;13:239-52.

(n27.)
Gardner EA, Johnston JA. Bupropion–an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24-9.

(n28.)
Walker PW, Cole JO, Gardner EA, Hughes AR, Johnston JA, Batey SR, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-65.

(n29.)
Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998;59:112-5.

(n30.)
Ferguson JM, Shrivastava RK, Stahl SM. Effects of double-blind treatment with nefazodone or sertraline on re-emergence of sexual dysfunction in depressed patients. New research program and abstracts of the 149th annual meeting of the American Psychiatric Association. New York: American Psychiatric Association, 1996.

(n31.)
Leiblum SR. Sexual desire disorders. New York: Guilford; 1988.

(n32.)
O’Donohue W, Dopke CA, Swingen DN. Psychotherapy for female sexual dysfunction: a review. Clin Psychol Rev 1997;17:537-66.

~~~~~~~~

By Robert L. Phillips Jr., M.D. gton Family Medicine Yakima, Washington llinois

Robert L. Phillips, JR., M.D., is an academic fellow and a clinical instructor in the Department of Family and Community Medicine at the University of Missouri-Columbia School of Medicine, Columbia. Dr. Phillips received his medical degree from the University of Florida College of Medicine, Gainesville, and completed a family practice residency program at the University of Missouri-Columbia School of Medicine

James R. Slaughter, M.D., is associate professor of psychiatry and chief of psychosomatic medicine at the University of Missouri-Columbia School of Medicine, Columbia, where he completed a psychiatry and neurology residency. Dr. Slaughter also received his medical degree from the University of Missouri-Columbia School of Medicine. He completed a fellowship in consultation-liaison psychiatry at Massachusetts General Hospital, Boston.


Copyright of American Family Physician is the property of American Academy of Family Physicians and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: American Family Physician, 08/15/2000, Vol. 62 Issue 4, p782, 5p

LOVE’S LITTLE BLUE HELPER

September 8th, 2007

Title: LOVE’S LITTLE BLUE HELPER ,  Newsweek, 00289604, 02/15/99, Vol. 133, Issue 7

Section: PERISCOPE

VITAL STATS

NEED A VALENTINE’S GIFT FOR THAT SPECIAL GUY? ONE IN 10 American men wants to try Viagra–seniors, and also boomers weaned on pharmacology and free love.

MAP: U.S. (Indicating: Viagra envy, Curiosity, Hard sell, Not interested)

~~~~~~~~

By MICHAEL J. WEISS


Copyright of Newsweek is the property of Newsweek and its content may not be copied or e-mailed to multiple sites or posted to a listserv without the copyright holder`s express written permission. However, users may print, download, or e-mail articles for individual use.
Source: Newsweek, 02/15/99, Vol. 133 Issue 7, p8, 1p

AGING BOOMERS, NEW MEDICINES DRAW MEN INTO HEALTH SPOTLIGHT

September 8th, 2007

Title: AGING BOOMERS, NEW MEDICINES DRAW MEN INTO HEALTH SPOTLIGHT ,  By: Frederick, James, Drug Store News, 01917587, 7/20/98, Vol. 20, Issue 11

Section: CHAIN PHARMACY: MEN’S HEALTH


The explosion of interest in Pfizer’s impotence drug viagra , a steadily aging baby boomer population and a growing interest in wellness and nutrition have put men’s health issues on the front burner and pulled thousands of men into the nation’s community pharmacies during the past two months.

viagra ’s runaway success took many by surprise. Within the first four weeks of its Food and Drug Administration approval and market launch, pharmacists had dispensed 1.05 million prescriptions for the impotence remedy, according to research from IMS America. That works out to 262,000 scripts a week, or nearly 40,000 per day–giving viagra a 98.1 percent share of the prescription drug market for erectile disfunction, according to IMS.

“Did viagra surprise everybody? Absolutely,” said one chain pharmacist. “But, let’s consider Prozac, which was also presented as a cure-all. Physicians were under some pressure from people to prescribe them Prozac, and this is sort of the same thing.

“Do I think all these men need viagra ? No,” he added. “But, 40 percent of the people who don’t need it will have better results than they did before, just based on the placebo effect. So, if $15 a tablet is worth it to them, who am I to say no?” he added with a laugh.

Also fueling new activity at the pharmacy counter is another quality-of-life pharmaceutical, Merck & Co.’s newly approved hair restorative in pill form, Propecia (finasteride), which for the past 10 years has been marketed in larger dosages under the brand name Proscar to treat prostate enlargement. Studies of Propecia’s ability to regrow hair showed success rates as high as 81 percent in some cases, according to reports.

Nevertheless, it will take more than the roaring success of viagra and other products to overcome the traditional reluctance of men to see a doctor about a worrisome condition, to learn more about preventive health and nutrition, or to alter lifelong habits that lead to poor health.


Early prevention is key to good health

Indeed, when it comes to the state of men’s health, Mickey Mantle may have said it best: “If I had known I was going to live this long,” the great Yankees slugger and outfielder is said to have uttered, “I would have taken better care of myself.”

For many men, that’s the sort of rueful expression that best sums up their attitudes toward preventive care and the maintenance of health. Compared with women, we men still exhibit a generally dismal level of awareness about or even interest in our own bodies.

This general lack of understanding and acceptance of the help that healthcare practitioners are trained to provide has a high cost, medical researchers say. “No matter how smart a man is, no matter what kind of professional status he’s achieved, he can still ignore things he shouldn’t ignore and pay the unnecessary consequences,” noted a report from The Male Health Institute in Irving, Texas.

“Those consequences can be serious,” the report went on. “Before age 65, men suffer 2.5 times more heart attacks than women. By age 65, one in three men suffers from high blood pressure, a primary risk for heart attacks. Yet men are less likely than women to have their blood pressure checked.

“One in nine men will be diagnosed with prostate cancer, yet few will have the easy and painless digital rectal exam and prostate-specific antigen blood test to detect it,” the report added. “Men are at greater risk of stress-related illnesses than women, yet only 20 percent of the people in the typical stress-management program are men. Every year, more than 50,000 men die of emphysema, one of the most preventable diseases. It has been estimated that more than 3 million men are walking around with early type II diabetes, a disease with major complications, and don’t know it. Clearly, the price of denial is high.”

Just as clearly, however, pharmacists can serve as a critical focal point for needed change in the way men deal with disease and preventive health measures. Said one pharmacist interviewed by Drug Store News, “If the pharmacist is doing his or her job and really counseling the patient … he or she can actually change the thinking of a whole population of people.”

Indeed, efforts by pharmacists to get men more involved in managing their own health and wellness could have profound effects, health experts agree. “The rate of male mortality could significantly be reduced if we could encourage men to seek treatment before symptoms have reached a critical stage,” noted Patrick Taylor, director of National Men’s Health Week and spokesman for the National Men’s Health Foundation.

Thus was born, four years ago, the idea for a national campaign to promote health education and interest in preventive care and wellness among men, Taylor said. The result was National Men’s Health Week, which is held each year in mid-June during the week leading up to Father’s Day. The event is funded by Men’s Health, a general-interest publication whose circulation has grown to 1.5 million in the decade since its launch.

“What gave rise to the idea of Men’s Health Week was this growing concern that men were not taking control of their health–particularly when it came to things such as getting regular health checks and going to the doctor,” Taylor explained.

The legendary reluctance of men to seek help from medical professionals has been the subject of much study, but few specific recommendations. Noted a spokesperson for the Male Health Institute, “Women depend on their ob/gyn specialists for female problems and learn the benefits of early detection for breast cancer through selfexams. Men, on the other hand, often ignore warning signs and symptoms until the problem becomes serious. Few men know where to go when they find a lump on a testicle or have trouble achieving an erection.”

In addition, noted this observer, “While the ob/gyn physician is trained to treat female problems, there is really no physician specially trained to deal with the wide variety of problems that face the man.”


Taking it like a man

Therein lies part of the problem. Between the majority of men and the healthcare community lies a great disconnect–a wide gulf created by men’s general reluctance to seek outside help and to trust in the advice of professionals. “From Little League on, you hear boys being told to